Kuehn Law is investigating Nektar Therapeutics for allegedly misleading shareholders about its REZOLVE-AA clinical trial. The lawsuit claims the company failed to follow trial protocols, overstated the trial's integrity, and made false public statements. This could impact investor trust and the company's stock value. Shareholders who bought stock before February 26, 2025, are encouraged to contact the law firm to protect their rights.
Ethereum's staking queues show a strong surge in demand to lock ETH, with 13.6 times more ETH waiting to enter staking than exit. The entry queue reached around 2.48 million ETH in September 2026, causing wait times of over 40 days, while the exit qu...
Duolingo's General Counsel recently sold over 8,000 shares, raising $1.2 million. This sale comes after the company's stock price fell by 51% over the past year, reflecting investor concerns or market challenges. The transaction highlights insider ac...
The iShares Global Tech ETF (IXN) has gained 34% despite a sharp drop in its price-to-earnings ratio from 29x to under 18x. It now trades at a high-teens P/E with a strong long-term EPS growth rate of 28.5% and increased global diversification. While...
Bitcoin recently reached $80,000, reigniting a debate between investor Jason Calacanis, who sees Bitcoin as a failed payment technology, and Michael Saylor, whose company Strategy holds 845,050 BTC and views it as digital capital for wealth preservat...
Bitcoin surged past $80,000 following the Senate's failure to advance the CLARITY Act and the Federal Reserve's interest rate hike. Arthur Hayes, former Bitmex co-founder, argued that higher rates put more money in the hands of wealthy investors, fue...
